VistaGen Therapeutics (VTGN) Stifel 2024 Healthcare Conference summary

Program updates and clinical progress

• Advancing a neuroscience pipeline with multiple clinical-stage, non-systemic, neurocircuitry-focused drug candidates targeting anxiety, depression, and menopausal hot flashes.

• PALISADE-3 and PALISADE-4 studies for acute social anxiety disorder are progressing well, with over 800 exposures and data readouts expected in the second half of next year.

• Enhanced protocol adherence and investigator training have been implemented to address prior study variability and improve data quality.

• Patient selection focuses on those severely affected by social anxiety disorder, with strict enrichment criteria to ensure robust efficacy assessment.

• The company is well-capitalized to fund ongoing pivotal studies through completion.

Study design, results, and regulatory strategy

• PALISADE-2 achieved the first positive phase III result for acute social anxiety disorder; PALISADE-1 was impacted by pandemic-related variability and protocol challenges.

• Improvements in drug administration, site management, and reduced reliance on CROs are expected to enhance outcomes in ongoing trials.

• Dose selection is based on clinical effects, safety profile, and specialized receptor activation studies, with higher doses chosen for future studies.

• Repeat-dose safety studies and human factor/device reliability studies are underway to address regulatory requirements for NDA submission in 2026.

• Device performance is validated through plume geometry, droplet size, and receptor activation studies, ensuring consistent drug delivery.

Safety, tolerability, and pipeline expansion

• Large open-label studies show a favorable safety profile, with headache as the most common adverse event and no significant systemic or abuse liabilities.

• No evidence of tolerance or scheduling concerns, supporting telehealth and digital engagement for future commercialization.

• Additional pipeline assets include PH10 for major depressive disorder and a non-hormonal therapy for menopausal hot flashes, both leveraging non-systemic, rapid-onset mechanisms.

• IND-enabling and phase 2B studies for these programs are planned, with protocol finalization and clinical entry targeted for the coming year.

• The approach aims to provide as-needed, on-demand therapies with minimal side effects, addressing unmet needs in neuropsychiatric and women's health markets.